





VM-1 vs. Traditional Biopsy Markers

The Marker Made for MRI
A new standard in post-biopsy visibility.



The Problem with Today's Markers

Traditional markers were not designed for long term tracking across multi-imaging modalities.

- Create **MRI artifacts** and interfere with imaging clarity
- **Mask or obscure tumors** on certain modalities
- Pose **allergy risks** to patients (up to 5%)
- Lack long-term visibility, especially in dense breast tissue

For high-risk patients who require ongoing MRI screening, these limitations can compromise care.

The **VM-1** Advantage



Category

Traditional Markers

MRI Visibility	May cause artifacts or distortion
Material	Titanium, nickel alloys
Multimodality Imaging	Often modality-limited
Migration Risk	Variable based on design
Patient Compability	Risk of allergy or discomfort
Use Case	Short-term site tracking

Clinical Proof

- **7-year follow-up** shows no change in position, brightness, or tumor bed
- **Enhanced MRI signal** over time improves long-term lesion localization
- **No black artifact, no shadowing**, even in dense breast tissue
- **First new FDA-approved soft tissue marker in nearly a decade**

Ideal for

- Radiologists managing **dense breast** or **genetically high-risk** patients
- Image centers focused on **multi-modality** requiring MRI imaging
- Reducing repeat biopsies and **improving continuity of care**

VM-1 by VizMark

Bright, artifact-free, and visible for years


Non-metallic, biocompatible PEEK + gadolinium

Visible in MRI, ultrasound, mammography, and CT


No migration in 7-year follow-up studies

Safe for life, no adverse effects reported

Long-term monitoring, especially for high-risk care



VM-1 in Dense Breast Tissue Mammogram view



VM-1 in a Benign Fibroadenoma Ultrasound view



Learn more at www.vizmark.com